Objectives of using prodrugs
Administering an inactive precursor into the patient's body solves several crucial pharmacokinetic problems that researchers encounter when developing standard drugs.
The main objectives of using this approach:
- Improvement of pharmacokinetic properties of the parent drug substance. Modifying the chemical structure allows the molecule to become more stable or, conversely, more soluble.
- Increased absorption and bioavailability. Many active metabolites are extremely poorly absorbed when taken orally. Masking problematic functional groups can significantly increase the fraction of the substance entering the systemic circulation.
- Ensuring targeted delivery to the site of action. Prodrugs are used to successfully overcome various histohematic barriers (such as the blood-brain barrier) that normally block the passage of the active compound.
Mechanism of action: from precursor to active form
The fundamental principle of any prodrug is that at the time of administration, it has no pharmacological activity. The therapeutic effect develops only after the molecule undergoes modifications within the body.
The process of converting an inactive precursor into an active compound (or active metabolite) occurs during normal metabolism. Most often, activation is carried out through the following biochemical reactions:
- Various options of hydrolysis in tissues and blood plasma.
- Hepatic transformation as the drug passes through the liver enzyme systems.
Example #1: ACE inhibitors and the absorption problem
A classic example of applying the prodrug concept in cardiology is the creation of enalapril (Enalaprilum).
From a chemical standpoint, the molecule contains a specific carboxyl group. The main problem is that the active metabolite itself — enalaprilat — has extremely low absorption rates in the gastrointestinal tract (only 10% of the taken dose is absorbed).
The solution was to create a prodrug: enalapril demonstrates an absorption level of 60% upon oral administration. After entering the bloodstream, it undergoes hydrolysis, resulting in the release of active enalaprilat in the body, which exerts a therapeutic effect.
Example #2: Valacyclovir and active transport
In antiviral therapy, the prodrug principle is brilliantly implemented using valacyclovir as an example.
Structurally, this drug represents a combination of an acyclovir molecule attached to a valine amino acid residue. This minor change fundamentally alters the mechanism of drug absorption in the intestine.
Unlike conventional acyclovir, valacyclovir is recognized by the body as a peptide and becomes a substrate for the intestinal oligopeptide transporter. Due to the involvement of active transport mechanisms, the bioavailability of the drug increases by more than 30%. Subsequently, the molecule undergoes hepatic transformation, where it is converted into the active antiviral compound.
Example #3: Levodopa and overcoming CNS barriers
Delivering drugs to the central nervous system is one of the most challenging tasks due to the presence of the tight blood-brain barrier (BBB).
When treating a number of neurological disorders, it is necessary to increase dopamine (Dopaminum) levels in the brain. However, the problem is that dopamine itself cannot cross the BBB.
The pharmacological solution was to use levodopa (Levodopa). As an inactive precursor, levodopa successfully crosses from the bloodstream into the tissues of the central nervous system. Once directly in the brain, the molecule is acted upon by the enzyme DOPA decarboxylase. As a result of this reaction, levodopa is converted into active dopamine right at the site of its required action.
Briefly: answers to topical questions
What are some examples of prodrugs activated by cytochrome P450 isoenzymes?
Examples of prodrugs activated by cytochrome P450 isoenzymes include clopidogrel, cyclophosphamide, and loratadine.
- Clopidogrel is an antithrombotic agent requiring metabolic activation involving the CYP2C19 isoenzyme.
- Cyclophosphamide is an antineoplastic agent hydroxylated in the liver to form active metabolites.
- Loratadine is a 2nd-generation antihistamine metabolized by the CYP3A4 isoenzyme to form the active form (desloratadine).
Which blood plasma enzymes carry out the hydrolysis of prodrugs?
The hydrolysis of prodrugs in blood plasma is carried out predominantly by non-microsomal enzymes. The main enzymes involved in this process include:
- Esterases — hydrolyze esters (e.g., convert the prodrug dabigatran etexilate into the active compound).
- Cholinesterase — a blood plasma enzyme involved in the rapid hydrolysis of certain drugs, such as procaine (Novocainum).
- Amidases — cleave amide bonds.
- Phosphatases — participate in breaking phosphate bonds.
Remembering three classic examples of prodrugs is easy based on their advantages: Enalapril improves percentages (from 10% to 60%), Valacyclovir uses valine for transport, Levodopa climbs into the brain (across the BBB).
Class and exam questions
Why do clinical practices prefer prescribing enalapril rather than ready-made enalaprilat?
This is due solely to pharmacokinetics. Active enalaprilat is absorbed in the GI tract by only 10%. Enalapril is absorbed by 60%, after which it spontaneously hydrolyzes in the body into active enalaprilat, providing the necessary concentration.
Due to what mechanism is valacyclovir absorbed better than conventional acyclovir?
The valacyclovir structure contains a valine amino acid residue. Because of this, the molecule is recognized by the oligopeptide transporter and absorbed via active transport, which increases bioavailability by more than 30%.
How does dopamine enter the brain upon administration of levodopa?
Dopamine itself does not cross the blood-brain barrier. Levodopa acts as a "trojan horse": it freely passes into CNS tissues, where it is converted into active dopamine by the action of the enzyme DOPA decarboxylase.
What else to study on this topic
- Mechanisms and types of hepatic transformation of drug substances.
- The role of hydrolysis in the activation of esters and amides.
- The functioning of oligopeptide transporters in the intestinal mucosa.
- Structural features of the blood-brain barrier and methods of overcoming it.
- The enzyme DOPA decarboxylase: localization and biological role.
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Prodrugs" and 5,304 other subject pages
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in "General Pharmacology"
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.